Deep learning based semi-automated model can predict lineage in patients with pituitary neuroendocrine tumors
Pituitary neuroendocrine tumors (PitNETs) represent the most prevalent category of neuroendocrine neoplasms. Contemporary classification paradigms emphasize transcription factor immunohistochemistry (IHC) as a cornerstone for molecular subtyping and risk stratification. However, the clinical adoption of this approach is hindered by the lack of standardized interpretative thresholds for antibody staining and limited global availability of specialized reagents, particularly in resource-limited settings. To address these challenges, we developed a semi-automated computational framework that predicts PitNET lineages directly from hematoxylin and eosin (H&E)-stained histology slides. The pipeline employs a dynamic confidence threshold: samples below this threshold undergo confirmatory IHC staining and manual pathological review, while those surpassing it are classified automatically. In prospective validation, this approach achieved a 68.9% reduction in diagnostic workload while maintaining 95.9% overall accuracy. Similar efficacy was observed in functional (74.4% workload reduction, 99.0% accuracy) and external (39.3% reduction, 95.1% accuracy) cohorts. Statistical analysis confirmed non-inferiority between semi-automated predictions and fully manual IHC-based evaluations in all the cohorts. Furthermore, we implemented a deep learning-based virtual IHC staining module, generating synthetic transcription factor images demonstrating high morphological concordance with ground-truth IHC slides. Notably, our computational analysis revealed distinct histomorphological correlates of lineages: SF1-lineage tumors exhibited homogeneous cellular architecture characterized by densely packed, compact cells with reduced cytoplasmic volume, whereas PIT1-lineage neoplasms displayed larger cells with expanded intercellular spacing and disorganized spatial arrangements.
Authors
- Nidan Qiao (ORCID: https://orcid.org/0000-0001-5478-3555)
- Jinhua Yu (ORCID: https://orcid.org/0000-0002-0654-6034)
- Hong Chen (ORCID: https://orcid.org/0000-0002-2441-0237)
- Hui Ma (ORCID: https://orcid.org/0000-0002-6232-4436)
- Xingli Deng (ORCID: https://orcid.org/0000-0003-1331-5549)
- Haixia Cheng (ORCID: https://orcid.org/0000-0002-1601-8673)
- Changzhen Jiang (ORCID: https://orcid.org/0000-0003-0018-7015)
- Junjun Li (ORCID: https://orcid.org/0000-0001-5543-4349)
- Chao Ma (ORCID: https://orcid.org/0000-0002-8459-2845)
- WU Guo-qing (ORCID: https://orcid.org/0000-0003-0583-8200)
- Yongfei Wang
- Shengyu Sun
- Xiaorong Yan (ORCID: https://orcid.org/0009-0000-7619-5703)
- Jianfang Li (ORCID: https://orcid.org/0000-0003-3789-5680)
- Z. Ning (ORCID: https://orcid.org/0009-0005-7618-7662)
- Zixiang Cong
Institutions
- Fujian Medical University (CN)
- Fudan University (CN)
- Kunming Medical University (CN)
- Nanjing General Hospital of Nanjing Military Command (CN)
- First Affiliated Hospital of Kunming Medical University (CN)
- National Center for Spinal Disorders (HU)
- First Affiliated Hospital of Fujian Medical University (CN)
- Ningxia Medical University (CN)
- Huashan Hospital (CN)
- Shanghai Center for Brain Science and Brain-Inspired Technology (CN)
- State Key Laboratory of Medical Neurobiology
Publication Details
- Journal
- Acta Neuropathologica Communications
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1186/s40478-025-02104-x
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China